(7) demonstrated that PCSK9 could affect the infiltration of lymphocytes, particularly CD8+ T cells, in tumor tissues by interfering with the major histocompatibility complex class I (MHC I) recycling pathway in the tumor cell membrane. This evidence concerns the gene CD8A and neoplasm.